Main Menu

Chemotherapy Clinical Trials

Open to recruitment

111 Trial: The 111 trial is a single group trial evaluating one cycle of adjuvant BEP chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours of the testis (NSGCTT).

BOXIT: This trial is a randomised phase III multi-centre double-blind placebo-controlled clinical trial.  The primary objective is to determine if the addition of the oral COX-2 inhibitor celecoxib to standard therapy is more effective in terms of disease recurrence at 3 years compared to standard therapy alone for the treatment of superficial TCC of the bladder in intermediate and high risk patients.

Triple Negative breast cancer Trial (TNT): TNT is a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR- and HER2- or known BRCA1 or BRCA 2 mutation associated breast cancer.

In set-up

POUT: Peri-Operative chemotherapy or sUrveillance in upper Tract urothelial cancer

In active follow-up

ABC: The NCRI Adjuvant Breast Cancer (ABC) International Trial: polychemotherapy and ovarian suppression in women with early breast cancer prescribed 5 years of tamoxifen.

AZURE: Does adjuvant zoledronic acid reduce recurrence in patients with high risk localised breast cancer?

BC2001: A randomised phase III study of radiotherapy with and without synchronous chemotherapy in muscle invasive bladder cancer.

DEVA: A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer patients.

HERA: The primary aim of the study is to compare disease-free survival (DFS) in patients with HER2 over expressing primary breast cancer randomised to Herceptin ® for 1 year or no further therapy or to Herceptin ® for 2 years or no further therapy. The trial recruited 5102 women with primary breast cancer that overexpresses HER2 (determined by IHC 3+ or FISH positive). Following the positive results at the interim analysis, all HERA patients on the observation arm have been offered the chance of receiving Herceptin treatment either for 1 year by direct assignment or by randomisation to either 1 or 2 years treatment, or they can choose to remain on the observation arm.

ICCG FEC Trial: Two randomised trials comparing CMF vs FEC in node positive and node negative primary breast cancer.

ICCG High Dose Study: Randomised trial of high dose therapy using cyclophosphamide, thiotepa and carboplatin in primary breast cancer patients with 4 or more histologically involved positive nodes.

ICCG HMFEC Trial: FE 50 C versus FE 75 C with or without sequential hormone therapy in women with node positive premenopausal breast cancer.

Penile TPF: A Phase II Trial of docetaxel, cisplatin & 5-fluorouracil chemotherapy (TPF) in locally advanced and metastatic carcinoma of the penis

SOFEA: A study of faslodex with or without concomitant arimidex versus exemestane following progression on non-steroidal aromatase inhibitors.

TACT: A randomised trial of standard anthracycline-based chemotherapy with fluorouracil, epirubicin and cyclophosphamide (FEC) or epirubicin and CMF (Epi-CMF) versus FEC followed by sequential docetaxel in women with early breast cancer.

TACT2: TACT2 is an NCRI Phase III randomised controlled trial of adjuvant chemotherapy in patients with early breast cancer.

TOPIC I: Trial of primary infusional chemotherapy.

TOPIC II: Trial of primary medical therapy for breast cancer.

TRAFIC: Trial of adjuvant 5FU infusional chemotherapy.

Closed to recruitment

ACTION : Adjuvant Cytotoxic Chemotherapy in Older Women (ACTION) is an NCRI Phase III randomised controlled trial testing the benefit and tolerability of adjuvant chemotherapy in patients aged 70 and over with early stage ER negative or ER weakly positive breast cancer.